IN RE ROTAVIRUS VACCINES ANTITRUST LITIGATION

  1. November 23, 2020

    Merck Again Denied In Bid To Arbitrate Vaccine Antitrust Suit

    A Pennsylvania federal judge on Friday refused for a second time to force doctors' practices into arbitration on proposed class action claims that Merck Sharp & Dohme Corp. unlawfully overpriced vaccines, finding that discovery mandated by the Third Circuit shows they're too far removed from the arbitration provisions.

  2. September 18, 2020

    Merck Says Vaccine Buyers Must Arbitrate Antitrust Suit

    Merck Sharp & Dohme Corp. is doubling down on its bid to arbitrate claims in a proposed class action alleging it violated federal antitrust law by selling overpriced vaccines after the Third Circuit revived its attempt to keep the case out of court.

  3. January 23, 2019

    Merck Can't Arbitrate Antitrust Suit Over Vaccine Bundles

    Merck Sharp & Dohme Corp. cannot force each individual in a proposed class action to arbitrate claims that its pediatric vaccine bundles with alleged artificially inflated price tags are anti-competitive, a Pennsylvania federal judge ruled Tuesday, finding that the plaintiffs never signed arbitration agreements.

  4. July 31, 2018

    Merck Says Vaccine Bundles Caused Low Prices, Not Harm

    Merck Sharp & Dohme Corp.'s bundling of pediatric vaccines isn't anti-competitive because it kept prices at "rock bottom" and didn't block other companies from competing, the drugmaker told a Pennsylvania federal court Monday in a bid to boot a proposed class action.

  5. April 26, 2018

    Merck Hit With Antitrust Suit Over Vaccine Bundle Discounts

    A pediatric medical practice accused Merck & Co. of locking down the market for the rotavirus vaccine by "bundling" the drug with other childhood vaccines it sells to practitioners at a discount, according to a proposed class action in Pennsylvania federal court Wednesday.